2021
DOI: 10.1038/s41398-021-01613-2
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review

Abstract: A recent increase in the literature regarding the evidence base for clozapine has made it increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we aimed at elucidating the state-of-the-art for clozapine with regard to efficacy, effectiveness, tolerability, and management of clozapine and clozapine-related adverse events in neuropsychiatric disorders. We conducted a systematic PRISMA-conforming quantitative meta-review of available meta-analytic evidence regarding clozapine … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
84
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 94 publications
(85 citation statements)
references
References 129 publications
0
84
0
1
Order By: Relevance
“…In secondary analyses, we merged the two CLOZUK cohorts and then stratified these individuals by their highest daily clozapine dose into three categories: (1) those taking a low dose (<300 mg/day), (2) those taking standard maintenance doses (300-600 mg/day), and (3) those individuals taking a higher dose than the usual maintenance dose (>600 mg/day)(28). For these analyses, we also included extra curation procedures ( Figure 1 ): First, we selected only those individuals with at least three assays in the clozapine monitoring system, spanning a period of 6 months or more.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…In secondary analyses, we merged the two CLOZUK cohorts and then stratified these individuals by their highest daily clozapine dose into three categories: (1) those taking a low dose (<300 mg/day), (2) those taking standard maintenance doses (300-600 mg/day), and (3) those individuals taking a higher dose than the usual maintenance dose (>600 mg/day)(28). For these analyses, we also included extra curation procedures ( Figure 1 ): First, we selected only those individuals with at least three assays in the clozapine monitoring system, spanning a period of 6 months or more.…”
Section: Methodsmentioning
confidence: 99%
“…Approximately one-third of individuals with schizophrenia experience symptoms that do not meaningfully improve after two courses of standard antipsychotics, a presentation often called treatment-resistant schizophrenia (TRS) (1). Clozapine, a second-generation antipsychotic, is the evidence-based treatment of choice for TRS, given its proven efficacy to treat symptoms that have not responded to other antipsychotics (2). However, despite its clear benefits in TRS, clozapine also has the potential to cause a range of adverse effects, and these are major contributors to treatment discontinuation (3).…”
Section: Introductionmentioning
confidence: 99%
“…For example, clozapine, an SGA, requires a risk–benefit analysis and weekly monitoring for months to years in order to assess for abnormal white blood cell counts due to the risk of agranulocytosis [ 163 ]. It also carries significant risks of seizure and cardiotoxicity [ 164 , 165 ]. Despite these known risks, it is considered a standard pharmacologic intervention for treatment-resistant schizophrenia, targeting mostly positive symptoms [ 164 ].…”
Section: Mdma In Schizophreniamentioning
confidence: 99%
“…It also carries significant risks of seizure and cardiotoxicity [ 164 , 165 ]. Despite these known risks, it is considered a standard pharmacologic intervention for treatment-resistant schizophrenia, targeting mostly positive symptoms [ 164 ]. Both positive and negative symptoms, when untreated, bear significant functional burden [ 1 , 2 , 7 , 44 ].…”
Section: Mdma In Schizophreniamentioning
confidence: 99%
“…Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia [ 1 ]. It is, however, associated with many peripheral adverse drug reactions (ADRs), including cardiac (myocarditis, cardiomyopathy and postural hypotension), metabolic (metabolic syndrome, obesity and diabetes), hypersalivation and gastrointestinal (constipation and ileus) [ 2 , 3 ]. Nose-to-brain (N2B) drug delivery offers a promising approach to the delivery of antipsychotics to the central nervous system (CNS) in the management of schizophrenia.…”
Section: Introductionmentioning
confidence: 99%